Aurum Ventures MKI provides value added growth capital to exceptional entrepreneurs within the fields of life-sciences and clean-tech. While we focus on investing in unique, cutting edge technologies that will mature into successful business companies, our investments reflect our own values, so we prefer investing in companies that, through their sound commercial propositions, also contribute to the well-being of mankind. Our team is comprised of senior and experienced hands-on executives who work actively with the portfolio companies in enhancing their strategic and execution capabilities. We typically take a long-term approach, understanding that ventures in the life sciences and clean tech take time to mature and be successful.
Aurum Ventures provides financing and other managerial resources to life science companies in all stages of development. Aurum Ventures’ focus is almost solely upon novel therapeutics, whether devices or pharmaceuticals, but from time to time we will also consider non-therapeutics such as agricultural biotechnology or bio energy. Aurum is continually entering into novel ventures and has a strong track record of partnering with portfolio companies to ensure timely clinical trials as required in most life science companies. Aurum will invest either alone or co- invest with other reliable partners either in a lead or follower position. Aurum will invest in both early and late stage projects, but our geographical focus is upon Israeli and Israel related opportunities.
Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent business man, philanthropist and entrepreneur. Morris Kahn is one of the founders of the Aurec Group, which has become a leading provider in the communication, media and information fields in Israel and around the world.